Key Takeaways Rocket Lab shares have declined 57% from their $151 peak, currently priced at $82.83 Wall Street consensus shows “Moderate Buy” with price targets averaging $110.29 First quarte
Shares of Rocket Lab (RKLB) began Monday’s session at $82.83, representing a significant 57% retreat from the $151 all-time peak reached in June. Despite this substantial correction, Wall Street analysts maintain optimism. Their collective price target of $110.29 suggests potential gains of approximately 49% from present levels.
The aerospace company holds a “Moderate Buy” consensus among market analysts, backed by three Strong Buy recommendations, thirteen Buy calls, five Hold positions, and a single Sell rating. Morgan Stanley maintained its “Overweight” stance in July, while New Street Research established a $150 target during May.
First quarter fiscal 2026 results showed revenue of $200.35 million, marking a 63.4% year-over-year surge and surpassing the Street’s $189.65 million projection. The firm met expectations for a loss of $0.07 per share.
The company’s backlog paints an encouraging picture. Rocket Lab secured 31 launch agreements during Q1 alone—exceeding its entire 2025 contract total. Overall backlog climbed to $2.2 billion, reflecting 108% growth compared to the prior-year quarter.
The adjusted EBITDA loss improved to $11.8 million, significantly better than the anticipated $26 million deficit. Following these results, no fewer than seven analysts lifted their price projections.
Recent contract victories warrant attention. Rocket Lab landed a $397 million agreement with the U.S. Space Force for developing, launching, and operating sophisticated flat-panel satellites utilizing its forthcoming Neutron rocket. An additional $266 million Space Force deal encompasses 12 suborbital missions plus up to six optional launches, with initial deployment expected by year-end.
Combined, Rocket Lab has captured roughly $663 million in Space Force business in recent months. The Neutron vehicle, critical to executing the larger agreement, remains in development without operational flights to date.
The company also successfully executed its 92nd Electron mission and 13th launch of 2026, placing a satellite into orbit for returning customer iQPS.
Profitability remains elusive. The firm recorded a $45 million net loss during Q1, with analysts projecting a full-year deficit of $0.26 per share. The stock’s price-to-sales multiple stands at 53—dramatically higher than the technology sector’s typical ratio near 7.
Insider transaction activity merits consideration. Throughout the previous three-month period, company insiders offloaded 3.85 million shares valued at roughly $362.8 million. SVP Arjun Kampani disposed of 88,000 shares during June at an average $107.98 price point. Portions of these sales related to tax liabilities from vesting equity compensation.
Institutional ownership accounts for 71.78% of outstanding shares. PensionDanmark expanded its position by 224.2% in Q2, purchasing 28,358 shares to reach a total holding of 41,008 shares valued at approximately $4.17 million.
With a beta coefficient of 2.60, the stock demonstrates pronounced volatility. The 52-week trading range spans from $37.57 to $151.00.
Rocket Lab will announce Q2 earnings following Monday’s closing bell on August 10. Key focus areas include revenue trajectory, Neutron development progress, and management commentary regarding the pathway to achieving profitability.
The post Rocket Lab (RKLB) Stock Down 57%: Should You Buy Before Monday’s Q2 Earnings? appeared first on Blockonomi.
